The promising early results on AstraZeneca's lung cancer drug AZD9291 won't convince anyone that the troubled company is on the turnaround trail, but it's a step in the right direction in what CEO Pascal Soriot promises will be a slow but steady reversal of its misfortunes.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
After the market closed on Friday, Achillion spread the word that the FDA is maintaining its clinical hold related to its once-hot hepatitis C drug sovaprevir, while distributing some unimpressive data on its combination approach.
Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $126.5 million payday to help complete a prospective transformative leap into marketing.
Researchers have posted early-stage data demonstrating that Roche's PD-L1 drug MPDL3280A--which takes the blinders off the immune system to spur an attack on cancer--scored a hopeful 26% response rate among a small group of non-small cell lung cancer patients who smoked.
Shares of Nektar Therapeutics took a nasty plunge Thursday evening after the biotech failed to convince investors that the Phase II flop of a top pain drug didn't tarnish the program's promise.
CRO inVentiv Health has launched a crowdsourced physician network, signing up doctors interested in late-stage research to speed the recruitment process for trial sponsors.
In an industry like pharma, you're only as good as your next big Phase III study. And hopes are running very, very high for the first round of late-stage results on the PCSK9 drug alirocumab from Sanofi and Regeneron.
Now that targeted therapies like Roche's Zelboraf and Bayer's Stivarga have raced through the FDA and into patients' hands, drug developers are relying less and less on old-fashioned randomized controlled trials.
The crucial late-stage failure--ramucirumab for breast cancer has been considered one of the pharma giant's top Phase III prospects--scuttles one of Eli Lilly's chief hopes for a major new drug approval application. The failure also follows several years of poor trial outcomes for Lilly, which has a reputation for taking expensive and very risky chances when it comes to late-stage development.